Login / Signup

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.

Pierre Quartier Dit MaireEkaterina AlexeevaTamàs ConstantinVyacheslav ChasnykNico WulffraatKarin PalmbladCarine WoutersHermine I BrunnerKatherine MarzanRayfel SchneiderGerd HorneffAlberto MartiniJordi AntónXiaoling WeiAlan SladeNicolino RupertoKen Abramsnull null
Published in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Reduction of canakinumab exposure may be feasible in patients who have achieved clinical remission of systemic JIA, but consistent interleukin-1 inhibition appears necessary to maintain this response.
Keyphrases